Personalized Therapy of Asthma

Guest Editor:

Dr. Luisa Brussino
Department of Medical Sciences, University of Turin, 10124 Torino, Italy

Deadline for manuscript submissions:
closed (25 January 2022)

Message from the Guest Editor

Dear colleagues,

Asthma is a complex multidisciplinary disease characterized by airway inflammation and remodelling, which is frequently misdiagnosed and underrecognized, thus affecting both public health and the patient's quality of life.

Despite many available treatments and adequate therapeutic compliance, some patients still complain of an uncontrolled, difficult to treat asthma. This has stimulated physicians and researchers to progressively improve their knowledge and identify different asthma phenotypes.

The introduction of biologic therapies as add-on treatment in severe asthma has further increased the need of novel biomarkers and asthma clustering, making the determination of asthma endotypes a key point for a tailored approach.

We are pleased to invite you to contribute to this special issue about personalized treatment for asthma. The aim of this special issue is to provide new evidence for asthma phenotyping, by finding new roles to the well-known biomarkers, as FeNO, blood eosinophils and inflammatory cytokines, and proposing new approaches in the pipeline.

I look forward to receiving your contributions.

Dr. Luisa Brussino
Guest Editor

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us